Navigation Links
Insmed Incorporated Provides Regulatory Update
Date:10/10/2011

MONMOUTH JUNCTION, N.J., Oct. 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the clinical hold previously placed on Insmed's phase 3 clinical trials for ARIKACE® (liposomal amikacin for inhalation) in Cystic Fibrosis (CF) patients with Pseudomonas lung infections. Insmed has not yet received a response from FDA regarding the clinical hold previously placed on Insmed's phase 3 clinical trials for ARIKACE in patients with non-tuberculous mycobacterial (NTM) lung disease.  

As announced on August 1, 2011, the clinical holds placed on ARIKACE in CF and NTM were based on an initial review by FDA of the interim results of a long-term rat inhalation carcinogenicity study reported to the agency by Insmed with ARIKACE.  At that time, FDA requested additional information on ARIKACE and data from the rat study.  Insmed submitted its complete response to this request before the end of August.

Insmed has been informed by FDA that, based on its review of the information provided to date, including the rat inhalation carcinogenicity study results, the agency has insufficient information to assess the risks for ARIKACE in CF patients.  FDA has requested additional information from the Company, including that Insmed conduct a dog inhalational 9-month toxicity study of ARIKACE to determine if the findings of the rat inhalation carcinogenicity study are also demonstrated in a non-rodent model, and to propose a CF patient population/disease state where the risk-benefit profile of ARIKACE may be more favorable.

"Insmed is in the process of assessing the impact that FDA's recent requests and the continuation of the clinical hold will have on our phase 3 clinical trials for ARIKACE in CF," said Timothy Whitten, President and CEO of Insmed.  "Once we have a better un
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
2. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
3. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
7. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
8. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
9. Insmed to Host Third Quarter 2010 Conference Call
10. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
11. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oregon , October 22, 2014 ... "Global Disposable Gloves Market (Product type, Form, End user, ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... global disposable gloves market. Based on key trends tracked, ... be valued at $7.9 billion by 2020, registering a ...
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
(Date:10/22/2014)... , Oct. 21, 2014   BioNano Genomics ... latest genomics research centers to purchase an ... the National Cancer Institute (NCI), NIH Intramural Sequencing ... Before Irys, obtaining a comprehensive view of a ... sequencing (NGS) does not deliver the scalability or ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
... more and are less likely ... to quit, ... Health shows the number of adult smokers in,the state is continuing to drop. ... has gone from 22.4,percent to a new low of 17 percent. Washington continues ...
... Continues to Decline; Strategic Business Unit Realignment, Completed; Clinical Update Provided ... ... Trial, BOCA RATON, Fla., Aug. 1 Nabi,Biopharmaceuticals ... recorded a net loss from continuing,operations of $5.3 million, or $0.09 per ...
Cached Medicine Technology:Adult Smoking Rate Continues Downward Trend 2Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 2Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 3Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 4Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 5Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 6Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 7Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 8Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 9Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 10Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 11Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 12Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 13
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/22/2014)... Dennis Thompson HealthDay ... U.S. health officials on Monday officially tightened guidelines for health ... no skin exposure and use of a respirator at all ... decided to issue the tougher rules after two Dallas nurses ... in the United States, Liberian national Thomas Eric Duncan. Nina ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... exposure causes genetic changes in breast cells , , THURSDAY, ... many plastic products used in households caused accelerated breast ... a condition that might predispose the animals to breast ... Butyl benzyl phthalate (BBP) is commonly used to soften ...
... occurrence in television shows and movies, but can watching it make ... Although research has shown ... there has been little direct neuroscientific support for this theory until ... Researchers at Columbia University Medical Centers Functional ...
... Program Sets Stage for Increased Visibility ... Among Shareholders and Investors, ... EMIS ) announced today that it has retained Adam,Friedman Associates, ... is a biopharmaceutical company that focuses on a,unique and improved ...
... Insmed Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... 5th Annual Global Follow-On Biologics,Conference on December 11, 2007 ... be held at the Hyatt Regency Hotel in Reston,Virginia, ... and will bring together corporate, regulatory, financial, and legal,experts ...
... SAN FRANCISCO, Calif., Dec. 6 Proteolix, Inc.,announced ... studies using,intravenous carfilzomib (PR-171) are to be presented ... Meeting in Atlanta, Georgia, December,8-10, 2007. Carfilzomib is ... for the treatment of multiple myeloma,lymphoma and solid ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) announced today details of ... chronic myelogenous leukemia,(CML) at the upcoming American Society of Hematology,s ... 8th - 11th, 2007 in,Atlanta, Georgia., , The schedule ... Date: ...
Cached Medicine News:Health News:Common Household Chemical Could Raise Breast Cancer Risk 2Health News:Common Household Chemical Could Raise Breast Cancer Risk 3Health News:This is your brain on violent media 2Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 2Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 3Health News:Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference 2Health News:Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 3Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 4
ELISA kit for detection of the cardiac marker Myoglobin. Kit features interchangeable reagents, E-Z Process performed at room temp, and results in less than 1 hour!...
... intended for the quantitative determination of prolactin ... in the diagnosis and treatment of disorders ... BioCheck Prolactin Quantitative Test is based on ... immunosorbent assay. The assay system utilized sheep ...
... assay is an immunometric ('sandwich') ... of Prolactin in human serum ... sample is bound by 2 ... epitopes. One antibody is attached ...
... ELISA Kit is enzyme immunoassay kit ... Prolactin (PRL) concentration in serum. Enzyme ... determination of many protein hormones in ... sensitive, reproducible, rapid and specific assay. ...
Medicine Products: